Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.

NCT Number	NCT04262206
Lead Sponsor	Duke University Collaborators: National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences
Conditions	Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Enrollment	20,000 participants
Start Date	2020-09-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-04